Clinical trial · no report yet · Phase 2
NCT03971474
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
- NCT03971474 ↗
- Completed
- SWOG Cancer Research Network
- 14 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 7 | |
| Podcasts | 6 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
- Interventions
- Docetaxel; Gemcitabine; Gemcitabine Hydrochloride; Pembrolizumab; Pemetrexed; Pemetrexed Disodium; Ramucirumab
- Arms
- Arm A (docetaxel, gemcitabine, ramucirumab, pemetrexed) · Active comparator
- Arm B (ramucirumab, pembrolizumab) · Experimental
- Enrollment
- 166
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- SWOG Cancer Research Network with National Cancer Institute (NCI)
- Start
- May 28, 2019
- Primary completion
- Apr 14, 2022
- Results posted
- Yes
- Registry record
- NCT03971474 · updated Sep 3, 2024